Cimetidine Dosing for Interstitial Cystitis
For interstitial cystitis/bladder pain syndrome, cimetidine should be dosed at 300 mg orally twice daily (600 mg total daily dose). 1
Evidence-Based Dosing Recommendation
The 2022 American Urological Association (AUA) guidelines classify cimetidine as a Grade B evidence treatment for IC/BPS, noting clinically significant improvement in symptoms, pain, and nocturia with no adverse events reported 1. However, the guidelines do not specify an exact dose.
The specific dosing comes from the pivotal research study that established cimetidine's efficacy: 300 mg orally twice daily for at least 1 month 2. In this study, 66% of patients experienced symptomatic relief, with 44% achieving complete and sustained response.
Important Clinical Context
Why This Dose Differs from FDA-Approved Uses
The FDA label for cimetidine addresses only its approved indications (duodenal ulcer, gastric ulcer, GERD, hypersecretory conditions) with doses ranging from 300 mg QID to 1600 mg daily 3. Cimetidine is NOT FDA-approved for IC/BPS, but the AUA guidelines support its off-label use based on clinical evidence.
Treatment Algorithm Position
- Start cimetidine after conservative measures fail (dietary modification, stress management, pelvic floor therapy)
- Consider it alongside or as an alternative to other oral agents:
- Amitriptyline 10-75 mg (Grade B, but significant side effects)
- Hydroxyzine (Grade C)
- Pentosan polysulfate (Grade B, FDA-approved but carries macular toxicity risk)
Duration and Response
- Minimum trial period: 1 month 2
- Response may occur within weeks, but sustained benefit requires continued therapy
- If no response after 1-2 months, consider alternative or combination therapy
Critical Caveats
Renal Impairment Adjustment
If the patient has severe renal impairment, reduce to 300 mg every 12 hours based on FDA guidance for cimetidine use in renal dysfunction 3. Further reduction may be needed with concurrent liver impairment.
Multimodal Approach Required
The AUA explicitly states that pain management alone does not constitute sufficient treatment 1. Cimetidine should be combined with:
- Behavioral interventions
- Pelvic floor physical therapy
- Stress management
- Bladder training
Drug Interactions
Cimetidine inhibits cytochrome P450 enzymes and can interact with multiple medications. Screen for interactions with warfarin, phenytoin, theophylline, and other drugs metabolized hepatically.
Practical Implementation
Starting regimen:
- Cimetidine 300 mg PO BID (morning and evening)
- Continue for minimum 1 month before assessing efficacy
- If partial response, continue and consider adding complementary therapies
- If no response after 2 months, transition to alternative oral agent or intravesical therapy
The favorable safety profile (no adverse events reported in IC/BPS studies) makes cimetidine a reasonable option when first-line conservative measures fail, particularly for patients who cannot tolerate amitriptyline's sedating effects or wish to avoid pentosan polysulfate's ocular risks 1, 2.